Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Roche Announces Second Cancer Immunotherapy Collaboration, This Time With Pieris

XTALKS NEWS

Roche

Pieris is set to receive $6.4 million in upfront capital from Roche, with up to $409 million to be paid out after the new drugs pass industry milestones.

Share this!

December 10, 2015 | by Sarah Massey, M.Sc.

Roche announced its second biotech collaboration this week with Boston-based Pieris pharmaceuticals. The company will be backing Pieris Pharmaceuticals’ Anticalin platform for the discovery of novel cancer immunotherapy drug targets.

It’s reported that Pieris will be responsible for preclinical phases of development, while Roche will use their expertise during clinical trials. Pieris is set to receive $6.4 million in upfront capital from Roche, with up to $409 million to be paid out after the new drugs pass industry milestones.

The deal will also help to bolster Pieris’ presence in the emerging field on immuno-oncology – a branch of immunotherapy – by having the pharmaceutical giant as one of their contributors. Following the announcement of the collaboration, shares in Pieris rose by 26 percent.



Pieris is currently developing made-to-order Anticalin-based therapies against specific cancer targets – a project that peaked Roche’s interest in the company. Pieris’ lead asset is a CD137/HER2 bispecific – known as PRS-343 – which has been developed to promote the patient’s immune system to launch an attack on the tumor, along with improve the efficacy of other cancer therapies. Concurrently, Roche has been developing its PD-L1 checkpoint inhibitor – atezolizumab – which is in the midst of late-stage studies.

Roche announced on Monday that they would be collaborated on immune-oncology drug discovery with SQZ – a deal worth more than $500 million if the company’s cell-squeezing technology is able to deliver. Pieris recently issued a press release outlining promising biomarker and safety data from the Phase I clinical trial of its Anticalin-based anemia drug, PRS-080.

“The decision by the leader in the development and commercialization of cancer biologics to collaborate with Pieris underscores the unique potential of Anticalin-based proteins as a differentiated class of immuno-oncology drugs,” said Stephen Yoder, CEO of Pieris. “As we initiate this collaboration, we will continue to vigorously advance our fully proprietary programs, including our lead CD137-HER2 bispecific.”

Sources:

WATCH & PARTICIPATE IN THESE WEBINARS 


 

FDA Expectations for 503B Outsourcing Facilities

Food Defense Vulnerability Assessment: 3 Things You Need to Know to Prepare for the Food Safety Modernization Act (FSMA)


Keywords: Roche, Immunotherapy, Drug Target


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Materialise and Tissue Regeneration Systems To Partner On 3-D Printed Tracheal Splints Clinical Trial

December 9, 2015 - 3-D printing software developer, Materialise, has announced it will be expanding its medical 3-D printing unit by partnering with startup, Tissue Regeneration Systems (TRS) to manufacture and test 3-D printed bioresorbable tracheal splints.


Cepheid’s Point-Of-Care Flu Diagnostic Granted FDA Approval

December 8, 2015 - An influenza diagnostic device – designed to rapidly diagnose viral infections at the doctor’s office – has received approval from the US Food and Drug Administration (FDA).


Roche Collaborates With SQZ Biotech Startup On Immuno-Oncology Treatments

December 8, 2015 - Pharmaceutical giant Roche, has developed a partnership with Cambridge, Massachusetts-based SQZ Biotech to take advantage of the startup’s new take on cell engineering.


LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.